The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
Abstract
Purpose: Survival of patients with multiple myeloma is highly heterogeneous, from periods of a few weeks to more than 10 years. We used gene expression profiles of myeloma cells obtained at diagnosis to identify broadly applicable prognostic markers. Patients and Methods: In a training set of 182 patients, we used supervised methods to identify individual genes associated with length of survival. A survival model was built from these genes. The validity of our model was assessed in our test set of 68 patients and in three independent cohorts comprising 853 patients with multiple myeloma. Results: The 15 strongest genes associated with the length of survival were used to calculate a risk score and to stratify patients into low-risk and high-risk groups. The survival-predictor score was significantly associated with survival in both the training and test sets and in the external validation cohorts. The Kaplan-Meier estimates of rates of survival at 3 years were 90.5% (95% CI, 85.6% to 95.3%) and 47.4% (95% CI, 33.5% to 60.1%), respectively, in our patients having a low risk or high risk independently of traditional prognostic factors. High-risk patients constituted a homogeneous biologic entity characterized by the overexpression of genes involved in cell cycle progression and its surveillance, whereas low-risk patients were heterogeneous and displayed hyperdiploid signatures. Conclusion: Gene expression–based survival prediction and molecular features associated with high-risk patients may be useful for developing prognostic markers and may provide basis to treat these patients with new targeted antimitotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationThe spindle-assembly checkpoint in space and time
Musacchio, A., & Salmon, E. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2163 · Cited by 2,227
Whitfield, M. L., Sherlock, G., Saldanha, A. J., Murray, J. I., Ball, C. A., Alexander, K. E., Matese, J. C., Perou, C. M., Hurt, M. M., Brown, P. O., et al. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.02-02-0030 · Cited by 1,527
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N., & Szallasi, Z. (2006) · Nature Genetics · doi:10.1038/ng1861 · Cited by 1,193
On the road to cancer: aneuploidy and the mitotic checkpoint
Kops, G. J. P. L., Weaver, B. A. A., & Cleveland, D. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1714 · Cited by 1,185
Feedback control of mitosis in budding yeast
Li, R., & Murray, A. W. (1991) · Cell · doi:10.1016/0092-8674(81)90015-5 · Cited by 1,174
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function
Hoyt, M. A., Totis, L., & Roberts, B. T. (1991) · Cell · doi:10.1016/0092-8674(81)90014-3 · Cited by 1,131
Shaughnessy, J. D., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, J. P., Kordsmeier, B., Randolph, C., Williams, D. R., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038430 · Cited by 914
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
Self-citationCommon markers of proliferation
Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650
Mad2 Overexpression Promotes Aneuploidy and Tumorigenesis in Mice
Sotillo, R., Hernando, E., Díaz-Rodríguez, E., Teruya-Feldstein, J., Cordón-Cardo, C., Lowe, S. W., & Benezra, R. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.019 · Cited by 612
Sampath, S. C., Ohi, R., Leismann, O., Salic, A., Pozniakovski, A., & Funabiki, H. (2004) · Cell · doi:10.1016/j.cell.2004.06.026 · Cited by 422
Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
Dynamic molecular linkers of the genome: the first decade of SMC proteins
Losada, A., & Hirano, T. (2005) · Genes & Development · doi:10.1101/gad.1320505 · Cited by 360
Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.-J., Harousseau, J.-L., Minvielle, S., & Bataille, R. (2002) · Blood · doi:10.1182/blood.v99.6.2185 · Cited by 358
Self-citationUbiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation
Reddy, S. K., Rape, M., Margansky, W. A., & Kirschner, M. W. (2007) · Nature · doi:10.1038/nature05734 · Cited by 356
Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling
Chng, W. J., Kumar, S., VanWier, S., Ahmann, G., Price-Troska, T., Henderson, K., Chung, T.-H., Kim, S., Mulligan, G., Bryant, B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4046 · Cited by 259
Neef, R., Gruneberg, U., Kopajtich, R., Li, X., Nigg, E. A., Sillje, H., & Barr, F. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1557 · Cited by 257
ZW10 links mitotic checkpoint signaling to the structural kinetochore
Kops, G. J. P. L., Kim, Y., Weaver, B. A. A., Mao, Y., McLeod, I., Yates, J. R., Tagaya, M., & Cleveland, D. W. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200411118 · Cited by 249
Nguyen, C., Rocha, D., Granjeaud, S., Baldit, M., Bernard, K., Naquet, P., & Jordan, B. R. (1995) · Genomics · doi:10.1006/geno.1995.1233 · Cited by 198
Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille, R., Durie, B. G., Grenier, J., & Sany, J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.80 · Cited by 163
Self-citationMULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL
Zandecki, M., Laï, J. L., & Facon, T. T. F. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-2939.x · Cited by 148
Magrangeas, F., Nasser, V., Avet‐Loiseau, H., Loriod, B., Decaux, O., Granjeaud, S., Bertucci, F., Birnbaum, D., Nguyen, C., Harousseau, J., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3385 · Cited by 136
Self-citationSaxena, A., Saffery, R., Wong, L. H., Kalitsis, P., & Choo, K. H. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200620200 · Cited by 113
Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin
Gadea, B. B., & RUDERMAN, J. V. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600702103 · Cited by 102
Inhibition of Aurora-B kinase activity by poly(ADP-ribosyl)ation in response to DNA damage
Monaco, L., Kolthur‐Seetharam, U., Loury, R., Murcia, J. M., de MURCIA, G., & Sassone‐Corsi, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506252102 · Cited by 97
Bernard, K. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.8.1435 · Cited by 78
Targeting aurora kinases as therapy in multiple myeloma
Shi, Y., Reiman, T., Li, W., Maxwell, C. A., Sen, S., Pilarski, L. M., Daniels‐Wells, T. R., Penichet, M. L., Feldman, R. I., & Lichtenstein, A. K. (2007) · Blood · doi:10.1182/blood-2006-07-037671 · Cited by 76
Chng, W. J., Kuehl, W. M., Bergsagel, P. L., & Fonseca, R. (2007) · Leukemia · doi:10.1038/sj.leu.2404934 · Cited by 34
Cited by
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Sonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W.-J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 928
Self-citationMAQC Consortium (2010) · Nature Biotechnology · doi:10.1038/nbt.1665 · Cited by 889
“and later on validated in three additional independent data set”
BackgroundMachine Learning in Drug Discovery: A Review
Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022) · Artificial Intelligence Review · doi:10.1007/s10462-021-10058-4 · Cited by 792
Metadata
- Authors
- Decaux, O., Lodé, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jézéquel, P., Attal, M., Harousseau, J.-L., Moreau, P., Bataille, R., Campion, L., Avet-Loiseau, H., & Minvielle, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-10
- Volume
- 26
- Issue
- 29
- Pages
- 4798-4805
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136810538
- Cited by
- 371
- References
- 32
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.